RU2017143580A3 - - Google Patents

Download PDF

Info

Publication number
RU2017143580A3
RU2017143580A3 RU2017143580A RU2017143580A RU2017143580A3 RU 2017143580 A3 RU2017143580 A3 RU 2017143580A3 RU 2017143580 A RU2017143580 A RU 2017143580A RU 2017143580 A RU2017143580 A RU 2017143580A RU 2017143580 A3 RU2017143580 A3 RU 2017143580A3
Authority
RU
Russia
Application number
RU2017143580A
Other versions
RU2017143580A (ru
RU2752497C2 (ru
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed filed Critical
Publication of RU2017143580A publication Critical patent/RU2017143580A/ru
Publication of RU2017143580A3 publication Critical patent/RU2017143580A3/ru
Application granted granted Critical
Publication of RU2752497C2 publication Critical patent/RU2752497C2/ru

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/0004Oxidoreductases (1.)
    • C12N9/0012Oxidoreductases (1.) acting on nitrogen containing compounds as donors (1.4, 1.5, 1.6, 1.7)
    • C12N9/0044Oxidoreductases (1.) acting on nitrogen containing compounds as donors (1.4, 1.5, 1.6, 1.7) acting on other nitrogen compounds as donors (1.7)
    • C12N9/0046Oxidoreductases (1.) acting on nitrogen containing compounds as donors (1.4, 1.5, 1.6, 1.7) acting on other nitrogen compounds as donors (1.7) with oxygen as acceptor (1.7.3)
    • C12N9/0048Uricase (1.7.3.3)
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43Enzymes; Proenzymes; Derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0019Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/02Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/11DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12YENZYMES
    • C12Y107/00Oxidoreductases acting on other nitrogenous compounds as donors (1.7)
    • C12Y107/03Oxidoreductases acting on other nitrogenous compounds as donors (1.7) with oxygen as acceptor (1.7.3)
    • C12Y107/03003Factor-independent urate hydroxylase (1.7.3.3), i.e. uricase
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Medicinal Chemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Dermatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Biophysics (AREA)
  • Plant Pathology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Physics & Mathematics (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
RU2017143580A 2015-05-15 2016-05-13 Улучшенные последовательности уриказы и способы лечения RU2752497C2 (ru)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562162280P 2015-05-15 2015-05-15
US62/162,280 2015-05-15
PCT/US2016/032415 WO2016187026A1 (en) 2015-05-15 2016-05-13 Improved uricase sequences and methods of treatment

Publications (3)

Publication Number Publication Date
RU2017143580A RU2017143580A (ru) 2019-06-17
RU2017143580A3 true RU2017143580A3 (ru) 2019-12-16
RU2752497C2 RU2752497C2 (ru) 2021-07-28

Family

ID=57320301

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2017143580A RU2752497C2 (ru) 2015-05-15 2016-05-13 Улучшенные последовательности уриказы и способы лечения

Country Status (18)

Country Link
US (3) US11098289B2 (ru)
EP (1) EP3294322A4 (ru)
JP (2) JP2018515101A (ru)
KR (1) KR20180002828A (ru)
CN (1) CN107614007B (ru)
AU (2) AU2016265677B2 (ru)
BR (1) BR112017024212A2 (ru)
CA (1) CA2984926A1 (ru)
CL (1) CL2017002774A1 (ru)
CO (1) CO2017012454A2 (ru)
HK (1) HK1252542A1 (ru)
IL (1) IL255403A0 (ru)
MX (1) MX2017014547A (ru)
MY (1) MY190411A (ru)
RU (1) RU2752497C2 (ru)
SG (2) SG10201910522TA (ru)
WO (1) WO2016187026A1 (ru)
ZA (1) ZA201708507B (ru)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US11098289B2 (en) 2015-05-15 2021-08-24 Medimmune, Llc Uricase sequences and methods of treatment
CN106554948B (zh) * 2015-09-29 2019-06-25 上海生物制品研究所有限责任公司 突变型尿酸酶、peg修饰的突变型尿酸酶及其应用
CN112410313A (zh) * 2019-08-20 2021-02-26 中国科学院上海药物研究所 一种高热稳定性尿酸酶及其应用
CN112646790A (zh) * 2019-10-11 2021-04-13 上海君实生物医药科技股份有限公司 改进的尿酸酶及其用于治疗高尿酸血症的方法
CN114746546B (zh) * 2019-10-29 2024-09-03 西湖生物医药科技(杭州)有限公司 工程化红细胞用于治疗痛风和高尿酸血症
WO2022081774A1 (en) * 2020-10-13 2022-04-21 University Of Florida Research Foundation, Incorporated Self-assembling uricase fusion peptides
MX2023005235A (es) 2020-11-03 2023-10-16 Protalix Ltd Uricasa modificada y usos de la misma.
CN114438048A (zh) * 2020-11-05 2022-05-06 重庆派金生物科技有限公司 尿酸氧化酶制剂及其应用
CN115197923A (zh) * 2021-04-09 2022-10-18 上海君实生物医药科技股份有限公司 尿酸酶、其药物组合物及其用途
KR20240049312A (ko) * 2021-07-08 2024-04-16 주식회사 프로앱텍 Arthrobacter globiformis 유래 요산산화효소-알부민 접합체, 그 제조방법 및 그 용도
KR20240083169A (ko) * 2021-09-23 2024-06-11 주식회사 프로앱텍 Apn 그룹을 포함하는 링커 및 이를 이용하여 제조된 기능성 폴리펩티드 변이체-알부민 컨쥬게이트
WO2023064732A1 (en) * 2021-10-15 2023-04-20 Georgia State University Research Foundation, Inc. Delivery of therapeutic recombinant uricase using nanoparticles

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH09154581A (ja) * 1995-12-05 1997-06-17 Asahi Chem Ind Co Ltd ウリカーゼを生産する実質上純粋な微生物
EP1100880B1 (en) 1998-08-06 2010-10-06 Duke University Urate oxidase
US6783965B1 (en) 2000-02-10 2004-08-31 Mountain View Pharmaceuticals, Inc. Aggregate-free urate oxidase for preparation of non-immunogenic polymer conjugates
RU2246318C2 (ru) 1998-08-06 2005-02-20 Маунтэн Вью Фармасьютикэлз, Инк. Конъюгаты peg-уриказы и их использование
ES2404074T3 (es) * 1998-08-06 2013-05-23 Mountain View Pharmaceuticals, Inc. Conjugados de peg-oxidasa de urato y su uso
CA2359345A1 (en) * 1999-01-14 2000-07-20 Bolder Biotechnology, Inc. Methods for making proteins containing free cysteine residues
US6913915B2 (en) * 2001-08-02 2005-07-05 Phoenix Pharmacologics, Inc. PEG-modified uricase
PL3321359T3 (pl) * 2005-04-11 2021-06-28 Horizon Pharma Rheumatology Llc Wariantowe postacie oksydazy moczanowej i ich zastosowanie
US8148123B2 (en) 2005-04-11 2012-04-03 Savient Pharmaceuticals, Inc. Methods for lowering elevated uric acid levels using intravenous injections of PEG-uricase
MX2007012548A (es) * 2005-04-11 2008-03-11 Savient Pharmaceuticals Inc Formas variantes de urato oxidasa y uso de las mismas.
US20130305398A1 (en) * 2012-02-16 2013-11-14 Marie Coffin Genes and uses for plant enhacement
EP3567113A1 (en) 2007-06-06 2019-11-13 Monsanto Technology LLC Genes and uses for plant enhancement
EP3482768A1 (en) 2009-06-25 2019-05-15 Horizon Pharma Rheumatology LLC Methods and kits for predicting infusion reaction risk and antibody-mediated loss of response by monitoring serum uric acid during pegylated uricase therapy
CN103184209B (zh) * 2011-12-27 2015-09-16 拜奥生物科技(上海)有限公司 人精氨酸酶和聚乙二醇化人精氨酸酶及其应用
US11098289B2 (en) 2015-05-15 2021-08-24 Medimmune, Llc Uricase sequences and methods of treatment

Also Published As

Publication number Publication date
US20180258406A1 (en) 2018-09-13
CL2017002774A1 (es) 2018-04-06
EP3294322A1 (en) 2018-03-21
WO2016187026A1 (en) 2016-11-24
BR112017024212A2 (pt) 2018-07-17
HK1252542A1 (zh) 2019-05-31
IL255403A0 (en) 2017-12-31
SG10201910522TA (en) 2020-01-30
RU2017143580A (ru) 2019-06-17
MY190411A (en) 2022-04-21
CA2984926A1 (en) 2016-11-24
ZA201708507B (en) 2018-11-28
JP2021184733A (ja) 2021-12-09
US20210254024A1 (en) 2021-08-19
CN107614007B (zh) 2022-03-25
AU2016265677B2 (en) 2021-12-09
US10883087B2 (en) 2021-01-05
AU2022200104A1 (en) 2022-02-03
CN107614007A (zh) 2018-01-19
CO2017012454A2 (es) 2018-04-30
US20190048327A1 (en) 2019-02-14
JP2018515101A (ja) 2018-06-14
SG11201708759YA (en) 2017-11-29
AU2016265677A1 (en) 2018-01-04
KR20180002828A (ko) 2018-01-08
EP3294322A4 (en) 2018-12-12
US11098289B2 (en) 2021-08-24
RU2752497C2 (ru) 2021-07-28
MX2017014547A (es) 2018-03-15

Similar Documents

Publication Publication Date Title
BR112018005706A2 (ru)
RU2017143580A3 (ru)
BR0009349B1 (ru)
BR0003928B1 (ru)
CN303069558S (ru)
CN303069098S (ru)
CN303068870S (ru)
CN303067918S (ru)
CN303066606S (ru)
CN303066196S (ru)
BR9906426B1 (ru)
BR9903804B1 (ru)
BR8302297Y1 (ru)
CN303071302S (ru)
BR0314869B1 (ru)
BR0110018B1 (ru)
BR0006866B1 (ru)
BR0009994B1 (ru)
BR0009942B1 (ru)
BR0009761B1 (ru)
BR0009757B1 (ru)
BR0009717B1 (ru)
BR0009649B1 (ru)
BR0009373B1 (ru)
BR0010150B1 (ru)